embecta Welcomes New Board Chair and Lead Independent Director

embecta Corp.’s Board of Directors has elected Devdatt “Dev” Kurdikar as chairman and Dr. Claire Pomeroy as lead independent director. Kurdikar succeeds LTG (Ret.) Non-Executive Chairman David F. Melcher, who retired due to commitments outside of his company-related duties.

Kurdikar, 57, joined BD (Becton, Dickinson and Company) in 2021 to lead the diabetes care business and became its president, CEO, and a board member when that business was spun off in 2022. He is also a board member of Zimmer Biomet Holdings Inc., AdvaMed (Advanced Medical Technology Association), and LMG Holdings (a Riverside Company portfolio firm).

“Through the combined efforts of our employees around the world, embecta has come a long way since our launch as an independent company nearly four years ago,” Kurdikar said. “I am honored that my fellow board members have placed their faith in me to continue to drive this progress while leading our transformation into a more broad-based medical supplies company.”

Dr. Pomeroy, 70, has been an embecta board member since its inception in 2022. Besides her role as lead independent director, she will continue to chair the Corporate Governance and Nominating Committee and serve on the Technology, Quality, and Regulatory Committee. Since 2013, Dr. Pomeroy has served as president of the Albert and Mary Lasker Foundation, a private organization seeking to improve health by accelerating support for medical research through the recognition of research excellence, public education, and advocacy. She is also a director of Haemonetics Corporation and serves on the Boards of Directors of the Sierra Health Foundation, Center for Women in Academic Medicine and Science, iBiology/Science Communication Lab, the Science Philanthropy Alliance, Morehouse School of Medicine, Research!America, and Geisinger College of Health Sciences.

“I wish to thank the board for their trust and support as we work together to carry out embecta’s mission to empower people with diabetes today while paving the way for a life unlimited for all,” Dr. Pomeroy stated. “Between Dev’s leadership and our board’s diversity of experience and shared sense of purpose, I have great confidence in our ability to advance embecta’s transformation and long-term success.”

embecta is a global company advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company. It employs approximately 2,000 employees worldwide.